Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Changes in Antithrombotic Therapy of Atrial Fibrillation in the Hospital in 2011-2012 and 2016-2017 (Pharmacoepidemiological Analysis)

https://doi.org/10.20996/1819-6446-2020-10-10

Full Text:

Abstract

Aim. To study the changes that have occurred in the pharmacotherapy of atrial fibrillation (AF) in the Saratov Region for 5 years by analyzing the antithrombotic therapy of patients who were admitted in a specialized department of the multidisciplinary hospital in Saratov in 2011-2012 and in 2016-2017.

Material and methods. A pharmacoepidemiological retrospective study was conducted. The object of the study was the medical records of inpatients (Form 003/y) with the diagnosis “Atrial fibrillation” (ICD-X code I48), that consecutively admitted to the cardiology department of the multidisciplinary hospital in Saratov from January 1, 2011 to December, 31, 2012 (n=211) and from January 1, 2016 to December, 31, 2017 (n=227). Criteria for inclusion in the study: patients over 18 years of age, established diagnosis of non-valvular AF of ischemic genesis. Exclusion criteria from the study: non-ischemic cardiomyopathy, thyrotoxicosis, congenital heart defects, rheumatic heart damage, acute coronary syndrome, endocarditis, myocarditis, pericarditis, pulmonary thromboembolism, the presence of prosthetic heart valve. Pharmacoepidemiological analysis was carried out for the drugs prescribed during hospitalization and given by doctors at discharge of patients from the hospital. The risk of ischemic stroke was assessed using the CHA2DS2-VASc score, and the risk of bleeding – according to the HAS-BLED score.

Results. When analyzing the risk of ischemic stroke, it was found that 100% of patients in 2011-2012 years and 98.2% in 2016-2017 years had indications for the prescription of oral anticoagulants (OAСs). In 2011-2012 there were no patients with a low risk of stroke (CHA2DS2-VASc=0). High risk of bleeding (HAS-BLED≥3) occurred in 4.7% of patients in 2011-2012 and in 10.6% in 2016-2017, however, due to the high risk of stroke, the refusal to prescribe OAC in these patients was inappropriate in accordance with the recommendations for the treatment of AF. In the group of patients with CHA2DS2-VASc=0 in 2016-2017 antiplatelet therapy was prescribed in 100% at the hospital stage and at discharge, which contradicts the guidelines, according to which antithrombotic therapy is not recommended to patients with CHA2DS2-VASc=0. In patients with CHA2DS2-VASc=1, a low percentage of anticoagulants prescription was noted. In 2016-2017 OACs were prescribed only in 12.5% of patients at all stages of observation. In 2011-2012 OAC alone was prescribed only to 1 person (20%) at the hospital stage, which does not comply with modern guidelines for the treatment of patients with AF, according to which patients with a risk score CHA2DS2-VASc=1 are recommended to receive OACs in the absence of contraindications. OACs prescription in group CHA2DS2-VASc≥2 occurred only in 15% of patients in 2011-2012 and in a third of patients in 2016-2017 (p<0.05). The frequency of isolated use of OACs significantly increased in 2016-2017 compared to 2011-2012 mainly due to the increase in the spectrum of direct OACs (DOACs) (p<0.05).

Conclusion. For 5 years there have been significant changes in the antithrombotic therapy of AF in the Saratov Region. The frequency of prescribing OACs according to indications has increased mainly due to the introduction of the DOACs into clinical practice. However, prevention of stroke remains insufficient.

About the Authors

O. V. Reshetko
Saratov State Medical University named after V.I. Razumovsky
Russian Federation

Olga V Reshetko – MD, PhD, Professor, Head of Chair of Pharmacology

Bolshaya Kazachya ul. 112, Saratov, 410012



A. V. Sokolov
Saratov State Medical University named after V.I. Razumovsky
Russian Federation

Alexey V. Sokolov – Post-Graduate Student, Chair of Pharmacology

Bolshaya Kazachya ul. 112, Saratov, 410012



N. V. Furman
Saratov State Medical University named after V.I. Razumovsky
Russian Federation

Nikolay V. Furman – MD, PhD, Assistant, Chair of Faculty Therapy

Bolshaya Kazachya ul. 112, Saratov, 410012



V. V. Agapov
Saratov State Clinical Cardiology Dispensary
Russian Federation

Valerii V. Agapov – MD, PhD, Chief Physician

Krymskaya ul. 15, Saratov, 410039



References

1. Bjorck S. Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, andwarfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103-8. DOI:10.1161/STROKEAHA.113.002329.

2. Haim M., Hoshen M., Reges O., et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486. DOI:10.1161/JAHA.114.001486.

3. Krijthe B.P., KunstA., Benjamin E.J., et al. Projections on the number of individuals with atrial fibrillation in the EuropeanUnion, from 2000 to 2060. Eur Heart J. 2013;34(35):2746-51. DOI:10.1093/eurheartj/eht280.

4. Conen D. Epidemiology of Atrial Fibrillation. Eur Heart J. 2018;39(16):1323-4. DOI:10.1093/eurheartj/ehy171.

5. Gadsbøll K., Gadsbøll K., Staerk L., et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899-906. DOI:10.1093/eurheartj/ehw658.

6. Proietti M., Laroche C., Nieuwlaat R., et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28-34. DOI:10.1016/j.ejim.2018.05.016.

7. Cowan J.C. Wu J., Hall M., et al. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39:2975-83. DOI:10.1093/eurheartj/ehy411.

8. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. DOI:10.1161/CIRCULATIONAHA.109.192667.

9. Nieuwlaat R., Capucci A., Camm A.J., et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422-34. DOI:10.1093/eurheartj/ehi505.

10. NabauerM., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-34. DOI:10.1093/europace/eun369.

11. Bokerija L.A., Revishvili A.Sh., Oganov R.G., et al. Clinical guidelines for the diagnosis and treatment of patients with atrial fibrillation. Vestnik Aritmologii. 2010;59:53-77 (In Russ.)

12. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial. Eur Heart J. 2010;31:967-75. DOI:10.1093/eurheartj/ehn599.

13. Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429. DOI:10.1093/eurheartj/ehq278.

14. Granger C.B., Alexander J.H., McMurray J.J., et al. For the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.

15. Patel M.R., Mahaffey K.W., Garg J., et al. For the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.

16. Camm A.J., Lip G.Y.H., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial. Eur Heart J. 2012;33(21):2719-47. DOI:10.1093/eurheartj/ehs253.

17. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. DOI:10.1093/eurheartj/ehw210.

18. Atrial fibrillation. Clinical guidelines [cited 12/01/2019]. Available at: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf (In Russ.)

19. Camm A.J., Accetta G., Ambrosio G. for the GARFIELD-AF Investigators, et al.Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103:307-14. DOI:10.1136/heartjnl-2016-309832.

20. Huisman M.V., Rothman K.J., Paquette M. et al.The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am CollCardiol 2017;69(7):777-85. doi: 10.1016/j.jacc.2016.11.061.

21. Apenteng P.N., Gao H., Hobbs F.D.R., et al. Temporal trends in antithrombotic treatment of realworld UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELDAF registry. BMJ Open. 2018;8:e018905. DOI:10.1136/bmjopen-2017-018905.

22. Boytsov S.A., Luk’yanov M.M., Yakushin S.S., et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatientpolyclinic practice. Cardiovascular Therapy and Prevention. 2014;13(6):44-50 (In Russ.) DOI:10.15829/1728-8800-2014-6-3-8.

23. Stepina E.V., Lukyanov M.M., Bichurina M.A., et al. Prescription of medications influencing prognosis in atrial fibrillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Rational Pharmacotherapy in Cardiology. 2017;13(2):146-54 (In Russ.) DOI:10.15829/1728-8800-2017-2-33-38.

24. Yakusevich V.V., Pozdnyakova E.M., Yakusevich V., et al. An outpatient with atrial fibrillation: key features. The first data of REKVAZA FP - Yaroslavl register. Rational Pharmacotherapy in Cardiology 2015;11(2):149-52 (In Russ.) DOI:10.20996/1819-6446-2015-11-2-149-152.

25. Martsevich S.Y., Navasardian A.R., Kutishenko N.P., et al. Studying atrial fibrillation on the basis of the “PROFILE” registry. Cardiovascular Therapy and Prevention. 2014;13(2):35-9 (In Russ.) DOI:10.15829/1728-8800-2014-2-35-39.

26. Korennova O.Y., Mal'cev S.N., Petrenko A.V., et al. Atrial fibrillation in real clinical practice: lessons from one regional registry. Difficult Patient. 2015;13(4):8-11 (In Russ.)

27. Grajfer I.V., Kuvshinova L.E., Dolotovskaya P.V., et al. Risk of thromboembolic complications and antithrombotic therapy in in-patients with permanent and recurrent atrial fibrillation in real clinical practice. Rational Pharmacotherapy in Cardiology. 2012;8(5):675-80 (In Russ.) DOI:10.20996/1819-6446-2012-8-5-675-680.


For citation:


Reshetko O.V., Sokolov A.V., Furman N.V., Agapov V.V. Changes in Antithrombotic Therapy of Atrial Fibrillation in the Hospital in 2011-2012 and 2016-2017 (Pharmacoepidemiological Analysis). Rational Pharmacotherapy in Cardiology. 2020;16(5):686-692. (In Russ.) https://doi.org/10.20996/1819-6446-2020-10-10

Views: 56


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)